middle.news
Charles River expands clinical bioanalysis with Frontage acquisition
10:13pm on Monday 9th of November, 2026 AEDT
•
Healthcare
Read Story
Charles River expands clinical bioanalysis with Frontage acquisition
10:13pm on Monday 9th of November, 2026 AEDT
Key Points
US$470 million upfront cash consideration plus up to US$75 million in contingent payments
Two Exton, Pennsylvania sites spanning approximately 150,000 square feet
About 340 employees and a CLIA-certified central laboratory included
Transaction expected to close in the first half of 2027, subject to approvals
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Charles River Laboratories International (NYSE:CRL)
OPEN ARTICLE